Ambio has secured regulatory approval from the U.S. Food and Drug Administration (FDA) for its generic version of Eli Lilly’s (NYSE: LLY) recombinant peptide Forteo (teriparatide), both of which are indicated for the treatment of osteoporosis. The subcutaneous injection will be marketed in partnership with Apotex.
According to the public report, Lilly’s original Forteo was launched in the U.S. market in 2002, maintaining a strong market presence until Alvogen’s Bonsity received approval in 2019. Last year, Forteo was one of Lilly’s top-selling products, contributing approximately USD 613 million to the company’s annual revenues.- Flcube.com
